RATIONALE: There is a large body of evidence indicating that the mesoaccumbens dopamine pathway is critically involved in the expression of behavioral sensitization to amphetamine and cocaine, but its role in the development of sensitization to psychostimulants is not that sound. Very few studies, however, have examined the role of dopamine transmission in 3,4-methylenedioxymethamphetamine (MDMA)-induced sensitization. OBJECTIVES: The effects of the D1 receptor antagonist SCH 23390 on the development and expression of MDMA-induced behavioral sensitization were investigated in rats. METHODS: During the development phase of sensitization, SCH 23390 was administered 15 min before every administration of MDMA. After 12 days of withdrawal, a MDMA challenge dose was given and locomotor activity was measured. In separate experiments, 15 min before the challenge injection of MDMA, SCH 23390 was administered either systemically or directly into the core of the nucleus accumbens (NAc) of MDMA-pretreated rats. RESULTS: SCH 23390 did not prevent the development of MDMA-induced behavioral sensitization but completely blocked the expression when given before the challenge dose of MDMA. The same results were obtained when SCH 23390 was locally applied into the core of the NAc. CONCLUSIONS: The present data suggest that D1 receptor stimulation is not critical for the development of long-term MDMA sensitization, in agreement with what has been reported for cocaine. By contrast, expression of sensitization depends on the activation of D1 receptors located in the NAc core.
RATIONALE: There is a large body of evidence indicating that the mesoaccumbens dopamine pathway is critically involved in the expression of behavioral sensitization to amphetamine and cocaine, but its role in the development of sensitization to psychostimulants is not that sound. Very few studies, however, have examined the role of dopamine transmission in 3,4-methylenedioxymethamphetamine (MDMA)-induced sensitization. OBJECTIVES: The effects of the D1 receptor antagonist SCH 23390 on the development and expression of MDMA-induced behavioral sensitization were investigated in rats. METHODS: During the development phase of sensitization, SCH 23390 was administered 15 min before every administration of MDMA. After 12 days of withdrawal, a MDMA challenge dose was given and locomotor activity was measured. In separate experiments, 15 min before the challenge injection of MDMA, SCH 23390 was administered either systemically or directly into the core of the nucleus accumbens (NAc) of MDMA-pretreated rats. RESULTS: SCH 23390 did not prevent the development of MDMA-induced behavioral sensitization but completely blocked the expression when given before the challenge dose of MDMA. The same results were obtained when SCH 23390 was locally applied into the core of the NAc. CONCLUSIONS: The present data suggest that D1 receptor stimulation is not critical for the development of long-term MDMA sensitization, in agreement with what has been reported for cocaine. By contrast, expression of sensitization depends on the activation of D1 receptors located in the NAc core.
Authors: C Lanteri; E L Doucet; S J Hernández Vallejo; G Godeheu; A-C Bobadilla; L Salomon; L Lanfumey; J-P Tassin Journal: Mol Psychiatry Date: 2013-08-20 Impact factor: 15.992
Authors: Stéphane Doly; Jesus Bertran-Gonzalez; Jacques Callebert; Alexandra Bruneau; Sophie Marie Banas; Arnauld Belmer; Katia Boutourlinsky; Denis Hervé; Jean-Marie Launay; Luc Maroteaux Journal: PLoS One Date: 2009-11-23 Impact factor: 3.240
Authors: Antonio Vidal-Infer; Concepción Roger-Sánchez; Manuel Daza-Losada; María A Aguilar; José Miñarro; Marta Rodríguez-Arias Journal: PLoS One Date: 2012-08-16 Impact factor: 3.240
Authors: Naeem Ur Rehman; Muzaffar Abbas; Mariya Al-Rashida; Ahmed Tokhi; Muhammad Awais Arshid; Muhammad Sona Khan; Izhar Ahmad; Khalid Rauf Journal: Drug Des Devel Ther Date: 2020-09-17 Impact factor: 4.162